The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing ...

In addition, Paul Stoffels, who led Galapagos’ transformation into a cell therapy company, will retire from his role within ...